Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
01 Giugno 2023 - 3:00PM
Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a
disruptive new platform for proteomics, today announced the launch
of the Proteograph XT Assay Kit, the latest proteomics assay
workflow for the Proteograph Product Suite. This new product
increases throughput without compromising performance, making it
possible for a single user to process hundreds of samples per week,
generating deep, unbiased proteomics data at scale. The release of
the Proteograph XT Assay Kit comes only a year and a half after the
launch of the company’s flagship Proteograph Assay Kit,
demonstrating Seer’s commitment to continued innovation that
reveals more of the proteome and unlocks meaningful biological
insights.
The Proteograph XT Assay Kit opens greater avenues for customers
to design large-scale studies that drive biological insights with a
unique combination of:
- Sight: Provides high-resolution insights into
the proteome at the peptide level, across a wide range of protein
concentrations with accuracy, precision, and reproducibility.
- Scope: Broadens the possibilities of novel
proteomic studies by enabling access to a diverse set of species
and sample types.
- Speed: More than doubles throughput with a
rapid, automated workflow to process samples quickly and easily
with high confidence and less than half the mass spec time.
- Scale: Enables large-scale studies powered for
discovery, with data management tools that scale with it.
“Seer’s Proteograph Product Suite provides the only proteomics
workflow that enables deep, unbiased proteomic content at scale, at
the peptide level. With the Proteograph XT, we are making the
proteome even more accessible, not just to the proteomics
community, but also to genomics researchers, who are eager to
deeply characterize genomic variants with functional proteomic
information, deepening their biological insights,” said Seer CEO
Omid Farokhzad. “The Proteograph XT workflow is automated,
flexible, and enables researchers to perform at-scale studies and
find answers to the questions they want to ask.”
With the Proteograph XT Assay Kit on the Proteograph Product
Suite, Seer makes the total cost of discovery affordable at a cost
approaching a penny per data point, with multiple data points per
protein. Adding deep, unbiased, peptide-level proteomics data to
research studies can provide unrivaled insight into biology,
disease progression, and targets for precision diagnostics and
therapeutics.
“Using the Proteograph XT has greatly enhanced our research
capabilities as we leverage the high throughput and automated
capability to conduct large-scale studies,” said Josh Coon, Ph.D.
Professor of Biomolecular Chemistry, University of
Wisconsin-Madison. “The XT allows us to achieve excellent and
increased proteomic depth with less analysis time. Beyond that,
collection of discovery-based MS data allows for the detection of
events like point mutations, post-translational modification, and
alternative splicing. I believe this capability uniquely positions
the combination of Seer and mass spectrometry to uncover actionable
information about the plasma proteome that will be critical to many
clinical applications including cancer and neurodegeneration, to
name a few. My lab is thrilled to be part of this groundbreaking
journey!"
Seer’s Proteograph Product Suite with the Proteograph XT Assay
Kit enables proteomics studies with an unprecedented combination of
sight, scope, speed and scale, allowing an unbiased interrogation
of the proteome to allow studies not previously possible. Seer’s
proprietary engineered nanoparticles deliver reproducible
performance across samples, labs, and experiments, providing
peptide-level information that is key to identifying protein
variants. The accompanying Proteograph Analysis Suite offers
cloud-scalable software for proteomic data analysis, visualization,
and generation of biological insights. The Proteograph Product
Suite with the Proteograph XT Assay Kit makes it easy to add
unbiased, deep, rapid proteomics studies at scale to any lab.
About SeerSeer™ is a life sciences company
developing transformative products that open a new gateway to the
proteome. Seer’s Proteograph™ Product Suite is an integrated
solution that includes proprietary engineered nanoparticles,
consumables, automation instrumentation and software to perform
deep, unbiased proteomic analysis at scale in a matter of hours.
Seer designed the Proteograph workflow to be efficient and easy to
use, leveraging widely adopted laboratory instrumentation to
provide a decentralized solution that can be incorporated by nearly
any lab. Seer’s Proteograph Product Suite is for research use only
and is not intended for diagnostic procedures. For more
information, please visit www.seer.bio.
Forward-Looking StatementsThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are based on Seer’s beliefs and
assumptions and on information currently available to it on the
date of this press release. Forward-looking statements may involve
known and unknown risks, uncertainties and other factors that may
cause Seer’s actual results, performance, or achievements to be
materially different from those expressed or implied by the
forward-looking statements. These statements include but are not
limited to statements regarding the processing of hundreds of
samples per week and generation of deep, large-scale studies,
across a range of sample types at unprecedented resolution, that
drive biological insights with a unique combination of sight,
scope, speed and scale. These and other risks are described more
fully in Seer’s filings with the Securities and Exchange Commission
(“SEC”) and other documents that Seer subsequently files with the
SEC from time to time. Except to the extent required by law, Seer
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Media Inquiries:Elizabeth
Eatonpr@seer.bio
Investor Inquiries:Carrie
Mendivilinvestor@seer.bio
Grafico Azioni Seer (NASDAQ:SEER)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Seer (NASDAQ:SEER)
Storico
Da Set 2023 a Set 2024